Bay Street News, December, 2018

Preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A show dramatic reductions in bleeds and infusions for first 12 […]

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 02, 2018 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today […]

VANCOUVER, British Columbia, Dec. 02, 2018 (GLOBE NEWSWIRE) — Nautilus Minerals Inc. (TSX:NUS, OTC:NUSMF Nasdaq Intl Designation) (the “Company” or […]

BOULDER, Colo., Dec. 02, 2018 (GLOBE NEWSWIRE) — miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the […]

Treatment with APL-2 in eculizumab-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) resulted in broad control of hemolysis and normalization of […]

– Two CRs, four PRs (46% ORR) observed in advanced AITL patients in Phase 2 trial of tipifarnib in PTCL […]

SINGAPORE, Dec. 03, 2018 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both […]

Results to be Further Discussed in Slide Webcast Today at 8:30 p.m. Pacific Time SOUTH SAN FRANCISCO, Calif., Dec. 02, […]

Overall Response Rate (ORR) of 46% in Patients Receiving the Combination  TLR4 Biomarker Continued to Show Higher Response Rate for […]

Results show high rates of Relapse Free Survival and Overall Survival in pediatric patients with acute leukemias with median follow-up […]